Promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease. Prevents mutant huntingtin-mediated proteasome dysfunction and reduces α
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parksinson's diseases.
Bodner et al.